Filing Flows › Atara Biotherapeutics (ATRA) › Q2 2025
Atara Biotherapeutics (ATRA) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 11, 2025
Atara Biotherapeutics (ATRA) reported revenue of $17.6M for the second quarter 2025 (Q2 2025), -39% from a year earlier and -82% from the quarter before. Operating margin was 18.2%, net earnings $2.4M (13.6% of revenue).
Atara Biotherapeutics, Q2 2025: revenue $17.6M (-39% year over year), operating margin 18.2%, net earnings $2.4M, operating cash flow −$7.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.6M | -82% | -39% |
| Operating profit | $3.2M | -92% | — |
| Net earnings | $2.4M | -94% | — |
| Operating cash flow | −$7.3M | — | — |
What changed
Revenue was $17.6M in Q2 2025, down 39% year over year and down 82% from the previous quarter.
Operating profit was $3.2M, a 18.2% margin (up 81.8 points year over year). Total costs fell 69% while revenue fell 39%. Net earnings were $2.4M. The effective tax rate was 0.1%.
Operating cash flow was −$7.3M. Non-cash charges added back $236K of depreciation and amortization and $2.8M of share-based compensation. Working capital and other items used $12.7M.
Questions
What was Atara Biotherapeutics' revenue in the second quarter 2025?
Atara Biotherapeutics (ATRA) reported revenue of $17.6M for the second quarter 2025 (Q2 2025), -39% from a year earlier and -82% from the quarter before.
Was Atara Biotherapeutics profitable in the second quarter 2025?
Operating profit was $3.2M (18.2% of revenue) and net earnings $2.4M.